wao logo

#


WAO News & Notes - 20076
Volume 4, Issue 6
4卷,第6

Medical Journal Review
WAO Now: What's New in the World of WAO
And In Other News . . .

医学杂志回顾
今日WAO:WAO领域新进展 AO领域新进展AO领域新进展
其他新闻

 

For Information about WAO Travel Grants to WAC 2007 in Bangkok, click here
有关
2007年度世界变态反应大会(曼谷)WAO差旅费补助的信息,点击这里

Visit the World Allergy Organization Exhibit Booth #28 during the XXVI EAACI Congress in Göteborg, Sweden, from 9-13 June 2007 and enter to win a free registration to the World Allergy Congress (WAC) in Bangkok, Thailand, 2-6 December 2007!
在第26EAACI大会(瑞典哥德堡, 200769日至13日)期间参观世界变态反应组织第28号展台,可以获得减免2007122日至6日在泰国曼谷举办的2007年度世界变态反应大会(WAC)注册费!

World Allergy Organization (WAO) Announces
世界变态反应组织(WAO)通告

WAO-Schering-Plough Corporation (SPC) &
WAO-European Academy of Allergology and Clinical Immunology (EAACI)
TRAVEL GRANTS
WAO-
先灵葆雅有限公司< (SPC) 以及
WAO-欧洲变态反应与临床免疫学会(EAACI)
差旅费补助

World Allergy Congress 2007, 2-6 December, Bangkok, Thailand>
2007年度世界变态反应大会,2007122日至6日,泰国曼谷

DEADLINE: 5 July 2007
截止日期: 200775

The World Allergy Organization (WAO), in partnerships with Schering-Plough Corporation (SPC) and the European Academy of Allergology and Clinical Immunology (EAACI), announces the WAO-SPC and WAO-EAACI Travel Grants for young scientists to attend WAO’s World Allergy Congress (WAC) in Bangkok, Thailand, 2-6 December 2007.
世界变态反应组织(WAO)与先灵葆雅有限公司(SPC)和欧洲变态反应与临床免疫学会(EAACI)合作,为了资助年轻科学工作者能参加在泰国曼谷 2007122日至6日期间举办的2007年度世界变态反应大会,特设立 WAO-SPCWAO-EAACI差旅费补助项目。

Applicants for travel grants must meet the following criteria:
申请差旅费必须符合以下条件:

  1. The applicant must be within five (5) years of his/her latest degree. 
  2. The applicant must submit an abstract. The abstract must be accepted for either oral or poster presentation at the Congress. Please visit the abstract submission website to submit your abstract. Only electronic submissions of abstracts are being accepted.
  1. 申请者毕业取得学位后的工作时限必须不满5
  2. 申请者必须递交一份摘要。该摘要必须为大会所接受(或者口头形式或者以壁报形式发表)。请登录摘要递交网站 递交您的摘要。仅接受以电子文档形式递交的摘要。

Travel grants are available to reduce personal costs involved in attending the Congress. They are not intended to cover the recipient’s total travel and accommodation costs.
差旅费补助可以用于降低与参加大会相关的个人开销。但它并非是对获得者所有旅费和食宿费用的全额报销。

Monetary awards will be given based on the recipient’s geographical location.
货币给予形式将基于接受者所在地理位置。

In addition to the monetary award, the Congress registration fee will be waived for award recipients. There will also be a luncheon in recognition of this and other travel awards, at which you will have the chance to meet other awardees and many renowned allergists.
除了在货币形式的补偿,奖学金获得者还将获得减免大会注册费。大会还将为本奖学金和其他差旅奖学金举办午餐会,届时您将有机会见到其他差旅奖学金获得者以及众多变态反应知名专家。

To apply for a WAO-SPC / WAO-EAACI Travel Grant to attend the WAC 2007, complete the Travel Grant Application and attach the appropriate supporting materials. The application and supporting materials must be received by 5 July 2007.  Please either fax (+1 414 276 3349) or email (congress@worldallergy.org) your application (if emailing, please note “Travel Grant Application - <FULL NAME>” in the subject line). 
如果您计划申请有关2007年度世界变态反应大会的WAO-SPC / WAO-EAACI差旅补助,请填写差旅费补助申请并附上适当的辅助材料。申请和辅助材料必须在 200775日 前寄达。投递申请的方式:传真(+1 414 276 3349)或电子邮件(congress@worldallergy.org)。(如果使用电子邮件,请在主题部分注明“差旅费补助申请-<全名>”)。

For Travel Grant Application Form, click here
有关差旅费补助的申请表格,请点击这里

Applications for travel grants will be reviewed in August at the time of the Abstract Review Meeting. Applicants will be notified in September 2007 regarding the status of their travel grant application. 
有关差旅费补助的所有申请将在八月份的摘要评审会议上进行评审。所有申请者的结果将在20079月予以通报。

For questions regarding travel grants, please contact the WAO Secretariat:
如果对于差旅费补助方面您仍有疑问,请与WAO秘书处联系:

World Allergy Organization
世界变态反应组织
555 East Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Tel
电话: +1 414 276 1791
Fax
传真: +1 414 276 3349
E-mail
电子邮件: congress@worldallergy.org
Web site
网站: www.worldallergy.org  


Medical Journal Reviews
医学杂志回顾

Prof. Richard F. Lockey, MD, WAO Web Editor-in-Chief, and Guest Reviewer Gary Hellermann, PhD, reviewed premier medical journal articles for practicing allergists.
Richard F. Lockey教授,医学博士,WAO网站主编,他为在业的变态反应科医生回顾了日前的医学杂志的一些重要文章。

1. AUTOLOGOUS NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHST) IN NEWLY DIAGNOSED TYPE 1 DIABETES MELLITUS
Guest Reviewer: Gary Hellermann, PhD

Type 1 diabetes mellitus (DM) is one of the most common autoimmune diseases and researchers have been attempting to circumvent the immune system’s destruction of pancreatic beta cells that characterizes the disease. One promising method is by AHST. This paper reports the results of a clinical trial in which 15 newly diagnosed DM patients, age 14-31 years, were given AHST and the progress of their disease followed for up to 36 months. All but one showed marked improvement as reflected by elevated C-peptide levels and freedom from insulin use. Side effects were neutropenia
, alopecia, nausea and, in one case, pneumonia that resolved with treatment. Editor’s comment: Immunointervention in type 1 DM at a young age while there is still a substantial number of beta cells appears to provide significant advantages, but long term side-effects still need to be examined. Voltarelli, JC et al. JAMA 2007; 297:1568.
译文
1. 自体非清髓性造血干细胞移植(AHST)在I型糖尿病初诊患者中的应用
客座评论家:Gary Hellermann博士
I
型糖尿病(DM)是最常见的自身免疫性疾病之一,其特征为免疫系统对胰岛β细胞的破坏,多年来科研人员一直在寻找方法试图避免这种破坏。一个很有前途的方法就是使用自体非清髓性造血干细胞移植(AHST)。本文报道了一项临床试验:15例初诊糖尿病患者,年龄14-31岁,给予AHST治疗后随访36个月。除1例患者外,其他患者均在以下指标上表现出明显改善:C肽水平升高,胰岛素使用减少。该治疗方法的副作用包括白细胞减少,脱发,恶心;有1例出现肺炎,经治疗后缓解。编者按:I型糖尿病青年患者尚存一定数量的胰岛β细胞,免疫干预治疗对这些患者具有明显优势,但其长期副作用仍有待进一步研究Voltarelli
, JC et al. JAMA 2007; 297:1568.

2. JACI AND ALLERGEN IMMUNOTHERAPY
The April 2007 JACI has multiple reviews and featured articles on allergen immunotherapy. The articles entitled are "Allergen Immunotherapy: Where Is It Now?," "Mechanisms of Allergen-Specific Immunotherapy," "Tradition and Innovation: Finding the Right Balance," and "Sublingual Immunotherapy: The Optimism and the Issues." In addition, there are articles entitled, "Recombinant Allergens For Immunotherapy," "Advances In Upper Airway Diseases and Allergen Immunotherapy," and "Allergic Rhinitis and Its Impact on Asthma Update: Allergen Immunotherapy." Likewise, there are three original articles on immunotherapy which include "Sublingual Immunotherapy With Grass Pollen Is Not Effective In Symptomatic Youngsters In Primary Care," "Update On the Current Status Of Peptide Immunotherapy," and "Successful Sublingual Immunotherapy With Birch Pollen Has Limited Effects On Concomitant Food Allergy To Apple and the Immune Response To the Bet v 1 homolog Mal d 1." Editor’s comment: This issue contains a multitude of articles on allergen immunotherapy and is must reading for the practicing allergist/immunologist. Nelson HS; Akdis M, et al; Durham SR; Pajno GB; Valenta R, et al; Nelson HS; Passalacqua G, et al; Röder E, et al; Larché M; Kinaciyan T, et al. JACI 2007; 119(4).
译文
2.
《变态反应与临床免疫学杂志》JACI和变应原免疫治疗
20074JACI刊登了多篇有关变应原免疫治疗的综述和文献。这些文章的题目包括《变应原免疫治疗:目前的地位如何?》,《变应原特异性免疫治疗的机制》,《传统与革新:找到恰当的平衡点》,《舌下免疫治疗:乐观与争议》。另外,还有一些其它方面的文章:《使用重组变应原进行免疫治疗》,《上呼吸道疾病和变应原免疫治疗的进展》,《有关过敏性鼻炎及其对哮喘影响的更新:变应原免疫治疗》。同时刊登的还有3篇文献原文,包括《在初级保健机构使用牧草花粉进行舌下免疫治疗草花粉不能有效控制青少年患者的症状》,《有关使用肽段进行变应原免疫治疗的现状更新》,《成功使用桦树花粉进行舌下免疫治疗对同时存在的苹果食物过敏疗效甚微,Bet v 1Mal d 1引发的免疫应答具有一致性》。编者按:该期期刊包含多篇有关变应原免疫治疗的文献,是变态反应/临床免疫专业医师的必读之物。Nelson HS; Akdis M, et al; Durham SR; Pajno GB; Valenta R, et al; Nelson HS; Passalacqua G, et al; Röder E, et al; Larché M; Kinaciyan T, et al. JACI 2007; 119(4).

3. INDACATEROL (I), A NOVEL INHALED β2-AGONIST, PROVIDES SUSTAINED 24-H BRONCHODILATION IN ASTHMA
42 patients were randomized to receive single doses of I (50, 100, 200 and 400 μg
) or placebo (P) via a hydrofluoroalkane pressurized metered-dose inhaler in a double-blind crossover study. Using primary efficacy comparisons, the mean percentage increases in FEV1 from placebo (P) and I, 200 and 400 μg, were 7.6 and 14.9%, respectively, at 30 min and 7.5% and 10.4%, respectively, at 21 h post-dose. At these doses, changes in mean FEV1 of I vs. P were significant from 5 min to 24 h, inclusive. I at 400 μg was statistically superior (P < 0.05) to other I doses at most time points. The highest mean differences in FEV1 of I from P were reached at 2-3 h post-dose. Once daily I (200 and 400 μg) provides 24-h bronchodilation, rapid onset, and good tolerability and safety. Editor’s comment: 24-h long-acting bronchodilators are on their way. Beeh KM, et al. Eur Respir J 2007; 29:871.
译文
3. INDACATEROL
I),全新吸入β2激动剂,可为哮喘患者提供持续24小时支气管扩张作用
本研究为双盲交叉研究,共有42名患者随机分组,分别接受单一剂量I50100200400 μg)或者安慰剂(P)治疗,给药时采用氢氟烷为推进剂的加压计量吸入装置。通过评价主要疗效指标发现:与安慰剂组相比,200400 μg剂量组的 FEV1平均改善率在用药后30分钟分别为7.6%14.9%,在用药后21小时分别为7.5%10.4%。从给药后5分钟到24小时,所有剂量治疗组获得的平均FEV1改善程度均明显优于安慰剂组。在大多数时间点,400 μg治疗组与其他剂量组相比具有统计学优势(P < 0.05)。I治疗组与安慰剂组相比,最大平均FEV1差值见于用药后2-3小时。每日一次I200400 μg)可以提供持续24小时的支气管扩张作用,起效迅速,并且具有良好耐受性和安全性。编者按:24小时长效支气管扩张剂正向我们走来。Beeh KM, et al. Eur Respir J 2007; 29:871.

4. EXHALED AIR TEMPERATURE IN ASTHMA: METHODS AND RELATIONSHIP WITH MARKERS OF DISEASE
57 children, 41 allergic mild asthmatics and 16 healthy controls, underwent exhaled air temperature and lung function measurements. The asthmatic children also underwent exhaled nitric oxide (NO) measurement and hypertonic saline sputum induction for eosinophils
. Exhaled temperatures were significantly higher in asthmatics than controls (30.18 ± 0.14 ºC vs. 27.47 ± 0.24 ºC (P < 0.001). There was a positive relationship between exhaled air temperature and both NO (r = 0.39; P = 0.01) and % EOS (r = 0.53; P = 0.04). The authors conclude that exhaled breath temperature is related to airway inflammation in asthma. Editor’s comment: Another article indicating that there is correlation between exhaled breath temperature and inflammation in asthma. Piacentini GL, et al. Clin Exp Allergy 2007; 37: 415.
译文
4.
哮喘患者呼出气体温度的测量方法及其与疾病标志物之间的关联
研究纳入57名儿童,包括41名轻度变应性哮喘患儿和16名健康对照,测量他们的呼出气体温度和肺功能指标 。哮喘患儿同时测定呼出一氧化氮(NO)浓度,并使用高渗盐水进行诱导检测嗜酸性细胞计数。与对照组相比,哮喘患儿呼出气体温度明显升高(30.18 ± 0.14 ºC vs. 27.47 ± 0.24 ºCP < 0.001)。在呼出气体温度和NOr = 0.39; P = 0.01)、嗜酸性细胞计数(r = 0.53; P = 0.04)之间具有明显正相关。作者认为在呼出气体温度与哮喘气道炎症之间存在关联。编者按:该文章又一次指出在呼出气体温度和哮喘炎症之间存在关联。Piacentini GL, et al. Clin Exp Allergy 2007; 37: 415.

5. RESPIRATORY HEAT AND MOISTURE LOSS (RHML) IS ASSOCIATED WITH EOSINOPILIC INFLAMMATION IN ASTHMA
23 subjects with asthma and 18 controls had RHML measured in a cross-sectional study using a device that combines temperature and humidity measurements during inspiration and expiration and allows precise control over inspiratory conditions and ventilatory pattern. They also underwent parallel measurements of exhaled NO (eNO), % sputum eosinophilia and exhaled breath condensate pH. Mean ±SD RHML was elevated in asthma (98.1±7.3 J·L-1) vs controls (91.9±4.5 J·L-1). The results correlated with % sputum eosinophilia (r = 0.73, P<0.0001) but not with eNO, EBC pH, FEV1 or FEV1 % predicted. Editor’s comment: Respiratory heat and moisture loss are elevated in patients with asthma. Noble DD, et al. Eur Respir J 2007; 29:676.
译文
5.
呼吸热量和湿度的丢失(RHML)与哮喘的嗜酸性细胞炎症相关
文章对23名哮喘患者和18名对照个体进行了有关RHML的交叉组合研究,研究使用的装置可以对个体吸气相和呼气相的温度、湿度进行精确测量,并可以对吸气条件和通气模式进行准确控制。 研究同时还测量了呼出一氧化氮(eNO),痰中嗜酸性细胞百分比以及呼气冷凝物PH值。与对照组相比(91.9±4.5 J·L-1),RHML的平均值±标准差在哮喘组明显升高(98.1±7.3 J·L-1)。该结果与痰中嗜酸性细胞百分比(r = 0.73, P<0.0001)相关,但与eNO、呼气冷凝物PH值、FEV1FEV1占预计值百分比无关。编者按:哮喘患者中呼吸热量和湿度的丢失情况加重。Noble DD, et al. Eur Respir J 2007; 29:676.

6. TIOTROPIUM (T) IN COMBINATION WITH PLACEBO (P), SALMETEROL (S), OR FLUTICASONE – SALMETEROL (FS) FOR TREATMENT OF COPD
This is a randomized, double-blind, placebo-controlled trial of 449 patients with moderate to severe COPD. They were treated for 1 year with T plus placebo (P), T + S, or T + FS. The primary end point was the number who experienced COPD exacerbations that required treatment with systemic steroids or antibiotics. The proportion of patients who experienced exacerbations did not differ in the 3 groups. T + FS improved lung function (P = 0.049) and disease-specific QOL (P = 0.01) and reduced the number of hospitalizations for COPD exacerbation and all-cause hospitalizations [incidence rate ratio, 0.67 (CI, 0.45 to 0.99)] compared with T + P. In contrast, T + S did not statistically improve lung function or hospitalization rates compared with T + P. The authors conclude that FS + T did not influence COPD exacerbation rates but did improve lung function, QOL, and hospitalization rates in patients with moderate to severe COPD. Editor’s comment: The jury is still out as to the best treatment for moderate to severe COPD. Physicians have to individualize treatment of COPD and what is appropriate and cost-effective for one patient may not be so for another. Aaron SD, et al. Ann Intern Med 2007; 146:545. Editorial, Criner GJ: 606.
译文
6.
观察噻托溴铵(T)联合安慰剂(P),沙美特罗(S)以及氟替卡/沙美特罗(FS)对COPD的治疗效果
本研究为随机、双盲、安慰剂对照试验,研究对象为449例中重度慢性阻塞性肺疾病患者。这些患者均接受为期1年的治疗:托溴铵+安慰剂,托溴铵+沙美特罗,托溴铵+氟替卡/沙美特罗。主要观察指标:由于COPD急性发作需要给予全身性糖皮质激素或抗生素的人次。结果显示有关COPD急性发作的患者比例在3个治疗组间没有差异。与T+P相比,T+FS可以更好地改善患者肺功能(P=0.049)以及疾病特异性生活质量评分(P=0.01),同时该组因COPD急性发作入院的人数以及因任何原因导致入院的人数均有所减少两组发病率之比0.67可信限0.450.99)〕。另外,与T+P相比,T+S未能显著改善肺功能和住院率。作者总结:FS+T不能改变COPD的急性发作率,但是使用本方法治疗中重度COPD患者可以改善肺功能、生活质量以及住院率。编者按:目前人们仍在寻找治疗中重度COPD患者的最佳方法。临床医师在治疗前需要对COPD患者进行个体化分析,值得注意的是:对某位患者恰当、收益高的方法也许并不适用于其他患者。Aaron SD, et al. Ann Intern Med 2007; 146:545. Editorial, Criner GJ: 606.

7. NEWS FOCUS IMMUNOLOGY: THE EDUCATION OF T CELLS
Guest Reviewer: Gary Hellermann
, PhD
When T lymphocytes are activated by antigen-presenting cells, they also receive instructions where to go. From the lymphoid tissue, they migrate to the exact area of the body under attack to play their part in the immune response. What are the signals that tell them this and where do they come from? Dendritic cells are the key because they identify the molecular address of the tissue in which the antigen was acquired and pass this information along to the T cell in the form of a pattern of chemokine receptors and cell-adhesion molecules. Editor’s comment: This clearly written review tells the story of how T cells are "educated" to home to a specific tissue address. Ferber, D. Science 2007; 316:191.
译文
7.
关于免疫学的新闻:T细胞接受的指令
客座评论家:Gary Hellermann博士
T细胞被抗原呈递细胞所激活,它们同时会接到前往何处的命令。随后,这些细胞从淋巴结迁移至机体正在遭受外界攻击的确切部位并发挥它们在免疫应答中的作用。那么,这些信号究竟是什么?来自何方?研究显示树突状细胞具有关键作用,这是因为树突状细胞不但可以识别获得抗原部位的分子学地址信息,而且可以把这一信息以趋化因子受体和细胞粘附分子的形式传递给T细胞。编者按:这篇综述清楚地告诉我们T细胞如何“被教会”自动导向某一特定组织。Ferber, D. Science 2007; 316:191.

8. FOXP3 CONTROLS REGULATORY T-CELL FUNCTION BY INTERACTING WITH AML1/RUNX1
Guest Reviewer: Gary Hellermann
, PhD
The key molecule that distinguishes a regulatory T cell is the transcription factor, Foxp3, which acts to maintain self-tolerance and suppress an overactive immune response. The molecular basis of Foxp3 function is a hot area of research, and the pieces of the puzzle are quickly falling into place. Suppression of IL-2 production by regulatory T cells is one aspect of Foxp3 control, and this article demonstrates by a masterful series of experiments that control is exerted directly through inhibition of the IL-2 transcription activator, AML1/Runx1 (acute myeloid leukaemia 1/Runt-related transcription factor. Editor’s comment: Foxp3 is the heavy hitter in regulatory T cells and this article adds one more to its list—suppression of IL-2 gene expression. Ono, M et al. Nature 2007; 446:685.
译文
8. FOXP3
通过与AML1/RUNX1的相互作用控制调节性T细胞的功能
客座评论家:Gary Hellermann博士
区分调节性T细胞的关键分子是转录因子Foxp3,该分子负责维持自身耐受并抑制过度免疫反应。由于Foxp3作用的分子生物学基础属于热门研究领域,其谜底得以迅速浮出水面。通过调节性T细胞抑制IL-2的产生是Foxp3发挥作用的一条途径,本文通过一系列有力的实验证实这种控制作用是通过抑制IL-2转录活化因子,AML1/Runx1(急性髓系白血病1/Runt相关转录因子)而直接实现的。编者按:Foxp3对调节性T细胞有重要调控作用,本文证实它同样对IL-2基因表达具有抑制作用。Ono, M et al. Nature 2007; 446:685.

9. AIRWAY SMOOTH MUSCLE (ASM) DYNAMICS: A COMMON PATHWAY OF AIRWAY OBSTRUCTION IN ASTHMA
This multi-authored paper reviews airways smooth muscle (ASM) dysfunction and its contribution to the pathophysiology of asthma. It indicates that there is a central role for ASM in the pathogenesis of airway hyperresponsiveness. Editor’s comment: This American Thoracic Society Workshop Report is extremely interesting and an in-depth discussion of the complex issues surrounding ASM and asthma. An SS, et al. Eur Respir J 2007; 29:834.
译文
9.
气道平滑肌(ASM)动力学:哮喘发生气道阻塞的常见途径
这篇由多位作者执笔完成的综述回顾了气道平滑肌(ASM)功能紊乱及其在哮喘病理生理学扮演的角色。文章指出ASM在气道高反应的发病机制中占据重要地位。编者按:这篇美国胸科学会研讨会报告值得关注,它对围绕ASM和哮喘的诸多复杂问题做了深入探讨。An SS, et al. Eur Respir J 2007; 29:834.

10. OSTEOIMMUNOLOGY
Osteoimmunology is an interdisciplinary research involving osteology (the branch of anatomy that deals with the structure and function of bones) and immunology. Receptor activator of nuclear factor κB ligand (RANKL), the main regulator of osteoclastogenesis, is the primary culprit responsible for the enhanced activation of osteoclasts and inflammatory diseases, such as occurs in rheumatoid arthritis. Activated T cells directly and indirectly increase the expression of RANKL thereby promoting osteoclastic activity and excessive bone loss in inflammatory and autoimmune diseases and cancer. Indeed, there is more and more evidence that osteoporosis is associated with alterations of the immune system. Other connections have been discovered in osteoimmunology and include the importance of osteoblasts in maintenance of the hematopoietic stem cell niche, lymphocyte development, and the functions of immune cells participating in osteoblast and osteoclast development. Cytokines, chemokines, transcription factors and co-stimulatory molecules are shared by both systems. Editor’s comment: Osteoimmunology is an innovative field and more research is needed to prevent and treat the bone loss which accompanies inflammatory and autoimmune diseases. Rauner M, et al. Int Arch Allergy Immunol 2007; 143:31.
译文
10.
骨骼免疫学
骨骼免疫学跨越多个学科,其研究领域涉及骨骼学(解剖学的分支,涵盖内容包括骨骼的结构和功能)和免疫学。细胞核因子κB受体活化因子配基(RANKL)是破骨细胞的主要调节因子,它是破骨细胞活性增强和炎性疾病的首要元凶,例如破骨细胞在类风湿性关节炎中的活性大大增强。活化T细胞可以直接或间接地增强RANKL基因的表达,从而增强破骨细胞活性,加重炎性和自身免疫性疾病、癌症中的骨质丢失。事实上,越来越多的证据表明:骨质疏松症与免疫系统的改变有关。目前发现在骨骼学和免疫学之间的其它关联包括:成骨细胞对维持造血干细胞存在环境以及淋巴细胞发育具有重要作用,免疫细胞参与成骨细胞和破骨细胞的发育。骨骼学和免疫学两个系统拥有共同的细胞因子、趋化因子、转录因子以及共刺激分子。编者按:骨骼免疫学是一个崭新的领域,在预防和治疗伴随炎性和自身免疫性疾病的骨质流失方面还需要进行更多的研究。Rauner M, et al. Int Arch Allergy Immunol 2007; 143:31.

11. THE STATUS OF US ALLERGY/IMMUNOLOGY PHYSICIANS (AIP) IN THE 21ST CENTURY: A REPORT FROM THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY (AAAAI) WORKFORCE COMMITTEE
The AAAAI has tracked the U.S. Allergy/Immunology Physician Workforce (AIPW) for the past 30 years. The current report concludes that there is an increase in diversity, training, and that 91% of AIP are board certified. Training programs are slowly increasing and the number of graduates has increased. Patients seen are more complex and less allergen immunotherapy administered. Personal, professional and economic satisfaction of the physician has increased. Even though the number of trainees is increasing, they are not expected to replace the diminishing practitioner supply amid growing U.S. population demand. Editor’s comment: The numbers of trainees are increasing, however, they are not sufficient to meet the increased needs for future care. Marshall GD. JACI 2007; 119:802.
译文
11. 21
世纪美国变态反应/免疫学临床医生(AIP)现状:来自美国变态反应,哮喘和免疫学会(AAAAI劳工委员会的报告
美国变态反应,哮喘和免疫学会(AAAAI)调查了过去30年间美国变态反应/免疫学临床医生(AIP的状况。报告结论:医生多样性和培训计划均在增加,有91AIP得到正规认证。培训项目的增长速度缓慢,专业毕业人数已经有所增加。同时,就诊患者的病情变得更加复杂,变应原免疫治疗减少。临床医生在个人、专业和经济等方面满意度增加。由于相对美国人口需求的增加,可供应的医生却日益减少,所以,尽管受训人员的数目正在增多,但仍远远不足。编者按:尽管受训人员的数目正在增多,但是这仍不足以满足未来日益增长的医疗需求。Marshall GD. JACI 2007; 119:802.



WAO Now: What's New in the World of WAO
今日WAOWAO领域新进展

allergic disease resource centerNew Synopsis Available - Vasculitis
可使用的新大纲-血管炎
Vasculitis syndromes are a clinical concern for allergists and clinical immunologists who are likely to be involved in managing hypersensitivity vasculitis; ANCA associated vasculitis, including Wegener’s granulomatosis and Churg-Strauss vasculitis (allergic angitis and granulomatosis); and temporal arteritis. To read an update about the diagnosis and management of these difficult conditions in a new synopsis authored by international expert Dr. Dennis Ledford of Tampa, USA , click here.
血管炎综合征作为一个临床关注点,受可能参与以下病症诊治的变态反应和临床免疫专业人员关注:超敏性血管炎;ANCA相关性血管炎,包括韦格纳肉芽肿和Churg-Strauss血管炎(变应性血管及肉芽肿);以及颞动脉炎。来自美国坦帕的国际专家,Dennis Ledford博士为我们编写了有关这些疑难病症诊断和治疗的最新大纲,如需阅读请 点击这里


WAO’s
Specific Immunotherapy Document
The World Allergy Organization (WAO) convened a group of experts to provide guidelines for the methodology of future immunotherapy studies to ensure that patients are treated based on sound scientific evidence and to minimize the risk of misusing limited financial resources for scientific studies. The document summarizes the recommendations for study design, patient selection, appropriate outcomes and statistical treatment to be used in planning and performing clinical trials with specific immunotherapy.
The document was recently published in the March 2007 Issue of Allergy: European Journal of Allergy and Clinical Immunology and is now available to you free from PubMed.
You may also access the document from WAO’s
Allergic Disease Resource Center.


WAO变应原特异性免疫治疗文件
世界变态反应组织(WAO)召集专家组对未来免疫治疗研究的方法学提供了指南,从而保证患者接受的治疗是基于健全的科学证据,并将错误使用科研研究有限资源的风险最小化。文件对特异性免疫治疗临床实验的设计和操作进行了有关科研设计、病例选择、恰当的结果、统计学治疗等概述。
本文件最近于20073月发表,名为《Allergy: European Journal of Allergy and Clinical Immunology》,目前可以在PubMed上免费获得。
您也可以访问WAO变态反应疾病资源中心获得该文件。


WAO Conversations
We have the pleasure of announcing two new interviews with well-respected allergists. Take a moment to listen to them share their extensive knowledge.

WAO 会谈
我们很高兴地宣布下面推出对两位著名变态反应学专家的访谈记录。邀请您来分享他们广袤的知识。

Ask the Expert – Exclusive Benefit to WAO Members
Ask the Expert
is a new online tool available exclusively to WAO Members. Directed by Professors Cassim Motala and Ruby Pawankar, this online service provides the opportunity to pose educational, scientific and medical questions about allergy, asthma, and clinical immunology to one of the many WAO volunteer experts located throughout the world. We invite all WAO Members to become a part of this online service. To Ask the Expert, click here.

专家咨询-本服务仅向WAO会员提供
专家咨询是一项全新的仅向WAO会员提供的在线工具。项目指导为Cassim Motala Ruby Pawankar教授,这项在线服务为访问者提供了向来自全世界的众多WAO专家志愿者请教有关变态反应、哮喘和临床免疫方面的教育,科研以及医学问题。我们邀请所有的WAO会员成为这项在线服务一部分。访问专家咨询,点击这里

Call for Applications
接受申请中

Short-Term Research Fellowship 2007 Applications
The World Allergy Organization (WAO) offers three Short-Term Research Fellowships, to commence in the latter half of 2007, to support junior allergists to visit a center of their choice to learn a research technique. The expected duration of each attachment is 2-3 weeks. WAO will contribute up to a maximum of $2,500 USD, to include travel and accommodations, for each Short-Term Fellowship.

Priority will be given to junior clinicians within five years of award of the most recent professional degree, who are specializing in allergy and who are affiliated to an academic department or clinical institute. Applicants must be current members of a WAO member society.

The Short-Term Fellowships will be applied to a project which meets one of the WAO Research Priorities:

    • Genetic factors involved in the development of allergic disease and response to treatment
    • Allergen characterization and standardization
    • Clinical and basic studies in allergy and asthma

Application forms may be downloaded here

Applications must be received by WAO Secretariat no later than 29 June 2007

WAO短期科研奖学金2007年度申请

世界变态反应组织(WAO)在2007年下半年开始提供三项短期科研奖学金以资助初年变态反 应医师前往他们所向往的医学中心进修并学习科研技术。进修持续时间以23周为宜。WAO将会为每位奖学金获得者资助最高2500美元的奖学金,包括旅行费用和食宿费用。
     
奖学金优先授予那些在近5年内获得专业学位的初年临床医师,其专业为变态反应,并且隶属于医学院相关科室或临床研究院。申请者必须是目前WAO成员学会的会员。
     
短期科研奖学金的申请目的必须符合以下WAO科研优先项目之一:

l                        参与变应性疾病发病及其治疗反应的遗传学因素

l                        变应原的鉴定和标准化

l                        过敏性鼻炎和哮喘的临床及基础研究

申请表可以从此处下载:链接

申请必须在 2007629送达WAO秘书处

Long-Term Research Fellowship
The World Allergy Organization (WAO) offers one Long-Term Research Fellowship, to commence in 2008. The Fellowship will support a junior allergist following an approved research program at a WAO proposed host center. WAO will contribute a monthly stipend of $1,700 US and once-yearly travel expenses between the home country and the host center.

Priority will be given to junior clinicians within five years of award of the most recent professional degree, who are specializing in allergy and who are affiliated with an academic department or clinical institute. Applicants must be active members of a WAO member society.

The Long-Term Fellowship will be applied to a project which meets one of the WAO Research Priorities:

    • Genetic factors involved in the development of allergic disease and response to treatment
    • Allergen characterization and standardization
    • Clinical and basic studies in allergy and asthma

Application forms including a list of host centers may be downloaded here

Applications must be received by WAO Secretariat no later than 30 September 2007

长期科研奖学金

世界变态反应组织(WAO)将于2008年开始提供一项长期科研奖学金。该奖学金将资助初年变态反 应医师前往某个WAO提名接待中心参加一项经批准的科研计划。WAO将会为奖学金获得者资助每月1700美金的津贴以及每年一次的往返旅费。

奖学金将优先授予那些在近5年内获得专业学位的初年临床医师,其专业为变态反应,并且隶属于医学院相关科室或临床研究院。同时,申请者必须是目前WAO成员学会的会员。

长期科研奖学金的申请目的必须符合以下WAO科研优先项目之一:

l                        参与变应性疾病发病及其治疗反应的遗传学因素

l                        变应原的鉴定和标准化

l                        过敏性鼻炎和哮喘的临床及基础研究

申请表格包括接待中心名单可由此处下载。

申请必须在 2007930送达WAO秘书处


The WAO Henning Løwenstein
Research Award 2007

The WAO Henning Løwenstein
Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy. WAO and ALK-Abelló will present the award at the World Allergy Congress in Bangkok, 2-6 December 2007.

The winner will receive EURO 20,000 together with a travel grant to attend the World Allergy Congress.

alk-abelloFor application guidelines, visit http://www.alk.abello.com/ and click on "The WAO Henning Løwenstein Research Award."
Deadline: 30 June 2007

WAO 2007年度Henning Løwenstein科研奖
WAO Henning Løwenstein 科研奖每2年颁发一次,将授予在变态反应领域做出卓越贡献的年轻科学家。WAOALK公司将在2007122-6日曼谷召开的世界变态反应大会上向获得者颁发本次奖项。
科研奖获得者将获得20,000欧元奖励,同时将被资助参加本次世界变态反应大会
访问这里 http://www.alk-abello.com/并点击"The WAO Henning Løwenstein 科研奖"即可获得申请指南
截止日期: 2007630

World Allergy Congress (WAC) Travel Grants
WAO, in partnership with Schering-Plough Corporation (SPC), the European Academy of Allergology
and Clinical Immunology (EAACI), and the American Academy of Allergy, Asthma and Immunology (AAAAI), is sponsoring Travel Grants for young scientists to attend WAO’s World Allergy Congress (WAC) in Bangkok, Thailand, 2-6 December 2007. For further information, click here.
Deadline: 5 July 2007

世界变态反应大会(WAC)差旅费补助
世界变态反应组织(WAO)与先灵葆雅有限公司(SPC),欧洲变态反应与临床免疫学会(EAACI),美国变态反应,哮喘与临床免疫学会(AAAAI)合作,为了资助年轻科学工作者能参加在WAO在泰国曼谷 20071226日期间举办的世界变态反应大会,特设立 了几项差旅费补助项目,如需更多信息,点击这里
截止日期: 200775


You are invited to attend…

邀请您参加

gloriaGLORIA Placements
GLORIA安排
British Society for Allergy and Clinical Immunology
英国变态反应和临床免疫学会
2007
72-4
Loughborough
, United Kingdom
International GLORIA Faculty国际GLORIA教员:
Allen P. Kaplan
Presentation
主讲:
Module 7: Angioedema
血管神经性水肿

XV Mexican National Congress of Pediatric Allergy and Asthma第十五届墨西哥儿科变态反应和哮喘全国大会
2007721-25
Merida
, Yuc., Mexico
International GLORIA Faculty国际GLORIA教员:
Bob Q. Lanier
Presentations:
Module 6: Food Allergy
食物过敏
Module 8: Anaphylaxis
严重过敏反应

International GLORIA is supported through unrestricted educational grants from:
世界变态反应论坛得到以下公司无私的教育资助

dyax & genzyme

nutricia shs international

dey


seminars and conferences
Seminars & Conferences Placement研究会和会议安排
Mexican National Congress on Clinical Immunology and Allergy
墨西哥临床免疫和变态反应全国大会
2007
627-30
Cancun, Mexico
WAO Invited Lecturer
WAO受邀讲者): Jay Portnoy
www.cmica.org

esp latin america
Emerging Societies Meeting - Cancun, Mexico
WAO's first Emerging Societies Meeting (ESM) of 2007 will take place during the LXI National Congress of Clinical Immunology and Allergy, 27-30 June 2007 in Cancun, Mexico. The ESM is a follow-up to the ESM held in Latin America in 2006 and will include representatives from Honduras, Guatemala, Cuba, El Salvador, Nicaragua and Martinique. This meeting is jointly funded by the American College of Allergy, Asthma and Immunology, the Mexican College of Allergy, Asthma and Clinical Immunology and the World Allergy Organization.

For more information on the Mexican College of Allergy, Asthma and Clinical Immunology’s meeting 27-30 June 2007, please click here.

新兴学会会议-墨西哥坎昆
WAO2007年度的第一次新兴学会会议(ESM)将于2007627-30日在墨西哥坎昆的临床免疫和变态反应全国大会期间召开。本次大会作为2006年在拉丁美洲召开ESM的延续,将会有来自洪都拉斯、危地马拉、古巴、萨尔瓦多、尼加拉瓜和马提尼克等国的代表参加。这次会议将由美国变态反应、哮喘和免疫学会(ACAAI)、墨西哥变态反应、哮喘和临床免疫学会以及世界变态反应组织共同资助举办。

如果需要有关墨西哥变态反应,哮喘和临床免疫学学院在2007627-30会议的更多信息,请点击这里


Sign up for Online Journal Subscription -
WAO and Hogrefe
& Huber Publishers are offering a limited number of free online subscriptions to Allergy & Clinical Immunology International - Journal of the World Allergy Organization for members in developing countries. If you are interested in receiving a complimentary, online subscription, please send an e-mail to info@worldallergy.org, noting "Free Journal Subscription" in the subject line, with the following details:

First name
Last (Family) name
Postal address
City, State/Province and postal code
Country
E-mail address
Name of Member Society


在线杂志订阅申请-
WAOHogrefe & Huber出版公司现为发展中国家的会员提供有限数量的Allergy & Clinical Immunology International - Journal of the World Allergy Organization免费在线订阅服务。如果您希望得到这份杂志的免费赠阅的电子版,请给我们发送e-mailinfo@worldallergy.org,注意在信件的主题栏写“Free Journal Subscription”,并详细注明以下资料:

名字
姓氏
邮政地址
市,州/省和邮政编码
国家
E-mail
地址
成员学会的名称

 


And In Other News 其他新闻

Two Allergy Book Reviews
两本变态反应学书评

Mayo Clinic Atlas of Immunofluorescence
in Dermatology: Patterns and Target Antigens
Mayo
临床皮肤学免疫荧光图集:图示和靶抗原
By: Amer N Kalaaji

Price: $98.95 USD
Available from: Mayo Clinic Scientific Press
定价: $98.95 美元
订购网址: Mayo Clinic Scientific Press

Reviewer书评作者:
Andrew Bagg
, MD
Division of Allergy and Immunology
University of South Florida College of Medicine, Tampa Florida

Description:
This Atlas reviews immunofluorescence
patterns found in many dermatologic conditions. The direct and indirect immunofluorescence findings and the target antigens are summarized in bullet point format.
说明:
本图册收集了有关许多皮肤疾病的免疫荧光图示。书中利用知识点格局对直接和间接免疫荧光检查发现以及靶抗原进行了总结。

Purpose:
The purpose is to provide information to aid in the understanding of the patterns found in immunodermatology
. It is designed to present the reader with a review of clinical dermatological diseases and a summary of immunofluorescence findings to facilitate learning and memory recall. It is a valuable resource for those preparing for boards and anyone interpreting immunofluorescence results.
目的:
本书目的是通过提供相关信息帮助读者理解免疫皮肤病的图像结果。为了方便读者的学习和记忆,书中对临床皮肤病学进行了回顾,并对免疫荧光的检查结果进行了总结。本书为那些准备学术会议和希望理解免疫荧光检查结果的人群提供了宝贵的资源。

Audience:
The Atlas targets dermatologists, pathologists, residents, and fellows. It should be used by those preparing for boards and physicians who need to interpret immunofluorescence
results to diagnose and treat patients.
读者:
本部图集面向:皮肤学专科医生,病理学家,住院医师以及研究生。对于那些准备学术会议的读者,以及需要通过理解免疫荧光检查结果对患者进行诊断和治疗的医生,本书将大有裨益。

Features:
The 75 pages cover the major diseases in immunodermatology
. Particular attention is given to staining patterns with numerous color photographs on every other page. For each disease there are clinical and direct and indirect immunofluorescence findings and target antigens summarized in an easy-to-follow bullet point format.
特色:
本书共75页,涵盖了免疫皮肤病中的所有主要疾病。值得注意的是,书中每隔一页都会使用大量彩色照片对染色方法进行介绍。书中还使用了简便易懂的知识点格局对每一种疾病的临床发现、直接和间接免疫荧光检查结果以及靶抗原进行了总结。

Assessment:
The color photographs and informative summaries found in the Atlas provide the student with an understanding of dermatologic immunofluorescence
. This book is an excellent resource for review and a convenient visual guide for diseases in immunodermatology.
评估:
本图集提供了大量彩色图片以及详实的总结,这为医学生提供了一个认识皮肤病学免疫荧光检查的机会。这本书出色地对免疫皮肤病学进行了回顾,可以作为该领域的易读性指南。


The Year in Allergy, Volume 3

变态反应时代,第3
Editors: S. Hasan Arshad, Stephen T. Holgate

ISBN:1 904392 60 1
ISSN:1477-8106

List Price: $99.95 USD
Available from: Atlas Medical Publishing
定价: $99.95 美元
订购网址: Atlas Medical Publishing

Reviewer书评作者:
Steven L. Cole, DO
Division of Allergy and Immunology
University of South Florida College of Medicine

Description:
This is the third installment of The Year in Allergy series and reviews the most recent research findings over the last 2 years. Each study reviewed is followed by a discussion of the scientific and clinical relevance of the findings.
说明:
本书是《变态反应时代》系列丛书的第三部分,对该领域中在最近2年发表的大部分科研发现进行了回顾。在每项研究的回顾之后,作者都配有对科研和临床相关发现的讨论内容。

Purpose:
The purpose of this book is to provide an overview of the major discoveries in the preceding 2 years relating to the mechanism, diagnosis, and treatment of allergic disorders. The book is divided into three parts, Epidemiology and Genetics (Part I), Pathophysiology
and Diseases (Part II), and Treatment Modalities for Allergic Diseases (Part III).
目的:
本书目的是对近2年中有关变应性疾病发病机制、诊断和治疗方面的重大发现进行一个全面的总结。本书共分三个部分:流行病学和遗传学(第一部分),病理生理学和疾病(第二部分),变应性疾病的治疗方法(第三部分)。

Audience:
The target audience includes researchers and clinicians from a wide array of interests in allergic disorders including specialists in allergy and immunology, dermatology, and pulmonology
. Experts in these subjects will glean valuable insight into not only their own interests, but also develop potential links to related topics as well.
读者:
本书面向读者包括:对变态反应疾病有着浓厚兴趣的所有科研人员和临床医师,包括变态反应和临床免疫学专业医师,皮肤病学以及呼吸病学专业医师。这些学科的专业人员对该领域的关注不仅出于个人的兴趣,更是希望找到与相关课题之间的潜在联系。

Features:
Each chapter includes an introduction which highlights the salient issues of the subject matter. The original publication reference is provided, and a summary of the methods is included for each paper. All studies reviewed contain an interpretation by the authors that focus on key findings and point out potential weaknesses of the information. Future directions are also discussed within the comments and conclusions section of each chapter.
特色:
每章包括突出题材内容的简介。书中还提供了原文的参考目录,并对所有文献中涉及的方法做了摘要描述。对所有研究的回顾分析都含有作者的注释:强调关键发现,同时指出文章的潜在缺陷。每一章节中的注释和结论部分还对未来发展方向做了讨论。

Assessment:
This is an ever-evolving discipline with numerous papers published each month from a wide array of journals, making it difficult for clinicians and researchers to read and digest all of them in a timely manner. This book succeeds in raising awareness of recent developments in the field of allergy, and it is organized in a manner that holds interest to a diverse group of readers. Clinicians can quickly review subject material directly pertaining to patient care, and researchers have access to critical reviews of the major findings in their field of interest. Although it is impossible to analyze every publication the world has to offer in allergic disorders, the authors of this book have done a tremendous job in the emphasis of papers with the most potential to impact the field.
评估:
由于每月从各种各样的期刊发表出的论文数量庞大,难以被临床医师和科研人员及时阅读并加以消化。本书的成功之处在于提高了读者对变态反应领域最新进展的掌握程度,本书的编撰成功地把握了来自不同专业领域读者的兴趣所在。通过使用本书,临床医师能够快速检索到有关诊治患者的有用信息,科研人员能够获得有关他们感兴趣领域的批判性评论。虽然对世界上有关变应性疾病的所有文献都逐一进行分析评论是不可能的,但是本书作者做了大量工作,对那些在本领域影响潜力最大的重要文献实现了这一目的。

Find more allergy book reviews on the WAO Website here.
WAO
网站上其它的变态反应学书评见此处

The World Allergy Organization's mission is to build a global alliance of allergy societies to advance excellence in clinical care, research, education and training. Visit us on the Web at http://www.worldallergy.org/
世界变态反应组织的使命是建立一个全球性的变态反应学会联盟,不断推动临床、科研、教学与培训工作的进步。欢迎您浏览我们的网站: http://www.worldallergy.org/

World Allergy Organization (WAO)
Secretariat
世界变态反应组织(
WAO)秘书处
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202-3823
Email: info@worldallergy.org
电子信箱info@worldallergy.org

You have received this message because you are a member of a WAO Member Society, you have subscribed for the monthly e-letter or had previous contact with the World Allergy Organization. If you would prefer not to receive further messages from WAO, please reply to this message with REMOVE in the subject line.
您因如下原因收到此次通讯:您是世界变态反应协会会员,或者您曾向世界变态反应协会订阅过电子月刊,或者您以前曾与世界变态反应协会进行过有关联系。如果您不希望继续收到来自世界变态反应协会的信息,请以删除为主题回复此邮件。

Made possible through an unrestricted educational grant from Novartis.